Michael Gelband’s Viking Therapeutics VKTX Stock Holding History

Michael Gelband’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.3M	Buy	393,000 +255,900	+187%	+$8.27M	0.1%	187
2026 Q1	$4.48M	Sell	137,100 -189,300	-58%	-$6.08M	0.04%	478
2025 Q4	$11.5M	Buy	326,400 +306,400	+1,532%	+$10.9M	0.09%	218
2025 Q3	$524K	Hold	20,000	–	–	0.01%	1169
2025 Q2	$531K	Hold	20,000	–	–	﹤0.01%	1136
2025 Q1	$484K	Sell	20,000 -294,300	-94%	-$9.3M	﹤0.01%	1115
2024 Q4	$12.7M	Buy	314,300 +163,200	+108%	+$9.31M	0.09%	216
2024 Q3	$9.58M	Sell	151,100 -123,400	-45%	-$7.24M	0.06%	245
2024 Q2	$14.5M	Buy	274,500 +245,100	+834%	+$16.1M	0.1%	180
2024 Q1	$2.42M	Buy	+29,400	New	+$1.31M	0.02%	626

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Michael Gelband's VKTX Position: Q2 2026 in Review

Michael Gelband increased its Viking Therapeutics (VKTX) stake by 419% in Q2 2026, buying an estimated $9.42M and bringing the position to 361,126 shares worth $14.1M. The position accounts for 0.09% of the portfolio, ranked #212.

Michael Gelband first reported a position in VKTX in Q2 2019 and has held it in 20 quarters since. The position peaked at $25.4M in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Michael Gelband held 361,126 shares of Viking Therapeutics worth $14.1M as of Q2 2026.
Michael Gelband bought 291,499 Viking Therapeutics shares in Q2 2026, an estimated $9.42M.
Viking Therapeutics made up 0.09% of Michael Gelband's portfolio in Q2 2026, its #212 holding.
Michael Gelband first reported a position in Viking Therapeutics in Q2 2019 and has held it in 20 quarters since.
Michael Gelband's Viking Therapeutics position peaked at $25.4M in Q4 2025.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.